Compare DAC & VERA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | DAC | VERA |
|---|---|---|
| Founded | 1972 | 2016 |
| Country | Greece | United States |
| Employees | N/A | N/A |
| Industry | Marine Transportation | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 2.6B | 3.0B |
| IPO Year | 2006 | 2021 |
| Metric | DAC | VERA |
|---|---|---|
| Price | $161.74 | $33.66 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 2 | 10 |
| Target Price | ★ $112.50 | $81.30 |
| AVG Volume (30 Days) | 101.2K | ★ 2.3M |
| Earning Date | 05-14-2026 | 05-06-2026 |
| Dividend Yield | ★ 3.00% | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | $472.48 |
| P/E Ratio | $4.01 | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $83.56 | $23.05 |
| 52 Week High | $163.64 | $56.05 |
| Indicator | DAC | VERA |
|---|---|---|
| Relative Strength Index (RSI) | 71.30 | 48.37 |
| Support Level | $121.29 | $33.43 |
| Resistance Level | N/A | $36.89 |
| Average True Range (ATR) | 2.89 | 1.96 |
| MACD | 0.27 | -0.10 |
| Stochastic Oscillator | 87.94 | 39.83 |
Danaos Corp is an international owner of containerships. It provides international seaborne transportation services by operating vessels in the containership sector of the shipping industry. The company's customers include HMM, MSC, Yang Ming, Hapag Lloyd, ZIM, Maersk, COSCO, OOCL, ONE, PIL, Sealead, Niledutch, Samudera, OSC, and Arkas. Geographically, the company operates in Australia, Asia, Europe, and America, with maximum revenue from the Australia-Asia region. It has two reporting segments: Container vessels and Drybulk vessels segment. It generates the majority of its revenue from Container vessels.
Vera Therapeutics Inc is a clinical stage biotechnology company. It is focused on developing and commercializing transformative treatments for patients with serious immunological diseases. The company's product candidate is atacicept, a fusion protein self-administered as a subcutaneous injection once weekly that blocks both B lymphocyte stimulator and a proliferation-inducing ligand, which stimulate B cells and plasma cells to produce autoantibodies contributing to certain autoimmune diseases.